Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 3/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | LCK | P06239 | 1/20 | 0.41 |
| ▸ | PPARD | Q03181 | 1/20 | 0.41 |
| ▸ | ZDHHC20 | Q5W0Z9 | 1/20 | 0.41 |
| ▸ | ZDHHC2 | Q9UIJ5 | 1/20 | 0.41 |
| ▸ | GPR84 | Q9NQS5 | 3/20 | 0.38 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.38 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.38 |
| ▸ | BCHE | P06276 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | LAP3 | P28838 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11571824 | 0.98 | LCK (0.44) | CA1CA2LCKPPARDZDHHC20 | |
| SCHEMBL28562560 | 0.98 | LCK (0.44) | CA1CA2LCKPPARDZDHHC20 | |
| SCHEMBL9245067 | 0.94 | CA2 (0.48) | CA1CA2LCKPPARDZDHHC20 | |
| SCHEMBL4537552 | 0.91 | LCK (0.42) | LCKPPARDZDHHC20ZDHHC2EPHX1 | |
| SCHEMBL27719303 | 0.90 | EPHX1 (0.44) | LCKPPARDZDHHC20ZDHHC2EPHX1 | |
| SCHEMBL11010077 | 0.90 | EPHX1 (0.44) | LCKPPARDZDHHC20ZDHHC2EPHX1 | |
| SCHEMBL771953 | 0.88 | EPHX1 (0.37) | CA1CA2EPHX1 | |
| SCHEMBL1478219 | 0.87 | CA1 (0.46) | CA1CA2EPHX1BCHE | |
| SCHEMBL1478217 | 0.87 | CA1 (0.46) | CA1CA2EPHX1BCHE | |
| SCHEMBL4188387 | 0.86 | CA1 (0.38) | CA1CA2EPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102256952-B | Arylcyclopropylacetamide derivatives useful as glucokinase activators | LILLY CO ELI | 2013-12-11 | — | — | CN | disclosed |
| EP-2379517-B1 | Arylcyclopropylacetamide derivatives useful as glucokinase activators | LILLY CO ELI (US) | 2013-08-28 | — | — | EP | disclosed |
| US-8314247-B2 | Hydrazone derivative | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2012-11-20 | — | — | US | disclosed |
| US-8119626-B2 | Oxime derivative and preparations thereof | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2012-02-21 | — | — | US | disclosed |
| CN-102256952-A | Arylcyclopropylacetamide derivatives useful as glucokinase activators | LILLY CO ELI | 2011-11-23 | — | — | CN | disclosed |
| US-20100099662-A1 | HYDRAZONE DERIVATIVE | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2010-04-22 | — | — | US | disclosed |
| US-20090291936-A1 | OXIME DERIVATIVE AND PREPARATIONS THEREOF | SUGAWARA KAZUTOSHI | 2009-11-26 | — | — | US | disclosed |
| EP-2105435-A1 | HYDRAZONE DERIVATIVE | Mitsubishi Tanabe Pharma Corporation (JP) | 2009-09-30 | — | — | EP | disclosed |
| US-7576108-B2 | Substituted arylcyclopropylacetamides as glucokinase activators | ELI LILLY AND COMPANY (US) | 2009-08-18 | — | — | US | disclosed |
| US-7514439-B2 | Oxime derivative and preparations thereof | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-04-07 | — | — | US | disclosed |
| US-20080132479-A1 | Oxime Derivative and Preparations Thereof | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2008-06-05 | — | — | US | disclosed |
| EP-1907387-A1 | AN OXIME DERIVATIVE AND PREPARATIONS THEREOF | Mitsubishi Tanabe Pharma Corporation (JP) | 2008-04-09 | — | — | EP | disclosed |
| WO-2007007886-A1 | AN OXIME DERIVATIVE AND PREPARATIONS THEREOF | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2007-01-18 | — | — | WO | disclosed |
| US-20060111353-A1 | Substituted arylcyclopropylacetamides as glucokinase activators | ELI LILLY AND COMPANY | 2006-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080132479-A1 | Oxime Derivative and Preparations Thereof | GCK, KHK, GCKR | CA1 1515/4885CA2 455/4885LCK 695/4885 |
| US-20090291936-A1 | OXIME DERIVATIVE AND PREPARATIONS THEREOF | GCK, KHK, GCKR | CA1 1515/4885CA2 455/4885LCK 695/4885 |
| US-20060111353-A1 | Substituted arylcyclopropylacetamides as glucokinase activators | GCK, GCKR, GALK1 | CA1 3133/4885CA2 1004/4885LCK 1376/4885 |
| US-20100099662-A1 | HYDRAZONE DERIVATIVE | GCK, GCKR, HK1 | CA1 1315/4885CA2 351/4885LCK 837/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.